Dr. Matthias Magoola, the founder and Managing Director of Dei BioPharma, has received recognition from the United States Patent and Trademark Office for his invention of the world’s first universal vaccine against Foot and Mouth Disease (FMD).
The patent application, accepted on January 7, 2025, secures exclusive rights to this pioneering vaccine, which is poised to save Uganda and other developing countries billions of shillings spent on importing FMD vaccines.
The vaccine, titled “Affordable Universal Fusion Universal Vaccine for Foot and Mouth Disease Infections,” addresses a critical need in global livestock industries.
FMD, an acute viral infection affecting food-producing animals like cattle, sheep, and goats, causes extensive economic losses due to its highly contagious nature. The novel vaccine combines all known epitopes of FMD-causing viruses, providing cross-protection against various serotypes and strains.
Dr. Magoola’s technology is unique, utilizing recombinant technology and RNA-based formulations that drastically reduce production costs while maintaining vaccine effectiveness. This breakthrough will make FMD vaccination more affordable and accessible worldwide, particularly in resource-constrained countries.
According to Dr. Magoola, the universal vaccine’s innovative design allows for a minimal dose, offering substantial savings compared to current vaccines.
The low cost of production also ensures it can be distributed globally, benefiting economies with large agricultural sectors. The vaccine’s potential impact extends beyond human health, offering a solution for controlling FMD and improving livestock productivity.
FMD has historically been a challenge in Uganda, where between 2015 and 2019, the country experienced 140 outbreaks, costing approximately USD 176 million annually in vaccination efforts.
With the implementation of this universal vaccine, Dr. Magoola believes Uganda will be better equipped to manage and prevent future outbreaks, saving not only financial resources but also reducing the need for emergency animal movement restrictions.
The development also builds on Dr. Magoola’s previous achievements in molecular biology, highlighted by his recent recognition at the International Molecular Biologist Awards in December 2024.
He was honored with the Best Researcher Award for his innovative work on mRNA-based therapeutic drugs and protein vaccines.
As Uganda continues to face FMD challenges, this breakthrough in vaccine development represents a significant step forward, enhancing both animal health and the economy.
